Editorial Commentary
Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
Abstract
Previously, local radiotherapy (RT) was only limited to palliate local symptoms, including bleeding or obstructive symptoms in metastatic prostate cancer patients. However, a population-based database and retrospective studies suggested that the local treatment of the prostate could improve survival in metastatic hormone-naïve prostate cancer with a small metastatic burden, ‘oligometastatic’ state (1-3). Recently two randomized trials demonstrated the efficacy of local RT to prostate in metastatic prostate cancer patients (4,5).